Tumours and tumour-like lesions of joints: Differential diagnoses in a paediatric population compared to adults

Objective: To determine the differential diagnosis of intra-articular tumours and tumour-like lesions in a paediatric population compared to adults. Methods: Retrospective review of children up to the age of 18 years with suspected intra-articular tumours and tumour-like lesions referred to a specialist musculoskeletal oncology service from January 2019 to August 2020. Data recorded included patient age and gender, lesion location and morphology (based on the classification system of Adams et al.), and the final diagnosis made either by image-guided biopsy/resection or by clinical and imaging features. Comparison was then made with a group of adults presenting during the same period. Results: 28 paediatric patients were included (12 males and 16 females with mean age 11.2 years, range 3–18 years). Joints involved were the knee (n = 22; 78.6%), ankle (n = 4; 14.3%), hip (n = 1; 3.6%) and elbow (n = 1; 3.6%). Lesion morphology was Type 1 (n = 18; 64.3%), Type 2 (n = 3; 10.7%), Type 3 (n = 1; 3.6%) and Type 4 (n = 5; 17.9%). Final diagnosis was made by image-guided biopsy/resection in 18 (64.3%) patients. The commonest neoplastic lesion was tenosynovial giant cell tumour (n = 11; 39.3%), followed by synovial haemangioma (n = 5; 17.9%). There was only a single malignant lesion, a case of synovial sarcoma. Of eight (28.6%) non-neoplastic lesions, three were diagnosed as juvenile idiopathic arthritis and three as non-specific synovitis. There was no difference compared to adults regarding gender, joint involved or lesion morphology, but there was a significant difference in final diagnoses (p < 0.001). The range of intra-articular tumours and tumour-like lesions in children differs from that in adults, although tenosynovial giant cell tumour is the commonest diagnosis in both groups and malignant lesions are rare. Advances in knowledgeart: In our series, ~16% of tumours and tumour-like lesions of joints occur in the paediatric population. Tenosynovial giant cell tumour remains the commonest diagnosis in children as in adults. Synovial haemangioma and juvenile idiopathic arthritis were the next commonest diagnoses in children, while primary synovial chondromatosis and reactive synovitis were the next commonest diagnoses in adults. Malignant lesions are rare in both groups.

Management of tenosynovial giant cell tumour of the foot and ankle

Aims Tenosynovial giant cell tumour (TGCT) is one of the most common soft-tissue tumours of the foot and ankle and can behave in a locally aggressive manner. Tumour control can be difficult, despite the various methods of treatment available. Since treatment guidelines are lacking, the aim of this study was to review the multidisciplinary management by presenting the largest series of TGCT of the foot and ankle to date from two specialized sarcoma centres. Methods The Oxford Tumour Registry and the Leiden University Medical Centre Sarcoma Registry were retrospectively reviewed for patients with histologically proven foot and ankle TGCT diagnosed between January 2002 and August 2019. Results A total of 84 patients were included. There were 39 men and 45 women with a mean age at primary treatment of 38.3 years (9 to 72). The median follow-up was 46.5 months (interquartile range (IQR) 21.3 to 82.3). Localized-type TGCT (n = 15) predominantly affected forefoot, whereas diffuse-type TGCT (Dt-TGCT) (n = 9) tended to panarticular involvement. TGCT was not included in the radiological differential diagnosis in 20% (n = 15/75). Most patients had open rather than arthroscopic surgery (76 vs 17). The highest recurrence rates were seen with Dt-TGCT (61%; n = 23/38), panarticular involvement (83%; n = 5/8), and after arthroscopy (47%; n = 8/17). Three (4%) fusions were carried out for osteochondral destruction by Dt-TGCT. There were 14 (16%) patients with Dt-TGCT who underwent systemic treatment, mostly in refractory cases (79%; n = 11). TGCT initially decreased or stabilized in 12 patients (86%), but progressed in five (36%) during follow-up; all five underwent subsequent surgery. Side effects were reported in 12 patients (86%). Conclusion We recommend open surgical excision as the primary treatment for TGCT of the foot and ankle, particularly in patients with Dt-TGCT with extra-articular involvement. Severe osteochondral destruction may justify salvage procedures, although these are not often undertaken. Systemic treatment is indicated for unresectable or refractory cases. However, side effects are commonly experienced, and relapses may occur once treatment has ceased. Cite this article: Bone Joint J 2021;103-B(4):788–794.

Chondroid tenosynovial giant cell tumour of the temporomandibular joint

Chondroid tenosynovial giant cell tumour (TGCT) is an extremely rare disease affecting the temporomandibular joint (TMJ). This report details the peri-operative findings and treatment with custom TMJ replacement of an initially misdiagnosed chondroid TGCT involving the TMJ.

RECURRENT GIANT CELL TUMOUR OF THE FLEXOR TENDON SHEATH OF THE DISTAL PALM – A CASE REPORT

Giant cell tumor of the tendon sheath is a common benign lesion of the hand. They are also known as tenosynovial giant cell tumours. Magnetic resonance imaging is the imaging modality of choice and the current treatment is surgical excision of the lesion. This lesion is particularly known for its high recurrence rates. Here, we present a case of a recurrent tenosynovial giant cell tumour of the flexor tendon sheath of the index finger at the distal palmar crease. Diagnosis was confirmed by MRI and the lesion was excised. Histopathology revealed a localized type of tenosynovial giant cell tumour.